Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced top-line results from its Phase I/II clinical trial testing the safety and efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE